麻豆原创

Drug Pipeline

Drug Pipeline 麻豆原创 Research Reports

Drug Pipeline 麻豆原创 Research Reports Analysis and Trends

Discovering and bringing new drugs to mainstream commercial market typically takes an average of 10-15 years of research and clinical development efforts. Drug developers need to make sure safe and effective drug available for patient in quick time. The first step is to target the protein available in the patient鈥檚 body that is associated with microorganism causing a disease, through tracking of cellular network of proteins an appropriate target for a drug is selected. Through a series of trials, right drug candidate got chosen.
According to 鈥淣OVARTIS鈥, bringing a new drug in market takes 14 years of research and cost around USD 2 billion, 10K+ clinical trials out of these, one leads to successful drug development.
Title Published Pages Price
Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 92 USD 2,000.00
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 50 USD 3,500.00
Liver Failure (Hepatic Insufficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Nov 30 2022 93 USD 2,000.00
RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: Landscape Analysis of Technologies, Targets, Business & Financing Nov 10 2022 418 USD 2,500.00
Osteonecrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 35 USD 2,000.00
Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 700 USD 2,500.00
Rubella (German Measles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 39 USD 2,000.00
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 218 USD 2,000.00
Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 308 USD 2,500.00
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 307 USD 2,500.00
Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 145 USD 2,000.00
Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 105 USD 2,000.00
Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 94 USD 2,000.00
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 119 USD 3,500.00
Gingivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 32 USD 2,000.00
Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 106 USD 2,000.00
Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 47 USD 3,500.00
Heterozygous familial hypercholesterolemia (heFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 63 USD 2,000.00
Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 116 USD 2,000.00
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 53 USD 3,500.00
Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 1127 USD 2,500.00
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 232 USD 2,000.00
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 69 USD 3,500.00
Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 286 USD 2,500.00
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 820 USD 2,000.00
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 57 USD 3,500.00
Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 142 USD 2,000.00
Pigmented Villonodular Synovitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 32 USD 2,000.00
Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 532 USD 2,500.00
Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 74 USD 2,000.00
Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 133 USD 2,000.00
Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 195 USD 2,000.00
Progressive Multifocal Leukoencephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 39 USD 2,000.00
Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 182 USD 2,000.00
Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 138 USD 2,000.00
Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 42 USD 2,000.00
Ankylosing Spondylitis (Bekhterev's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 140 USD 2,000.00
Anaplastic Oligoastrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 34 USD 2,000.00
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 113 USD 3,500.00
Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 643 USD 2,500.00
Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 204 USD 2,000.00
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 53 USD 3,500.00
Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 210 USD 2,000.00
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 1814 USD 2,000.00
Hepatitis C Virus Envelope Protein E2 Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 35 USD 3,500.00
Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 548 USD 2,500.00
Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 628 USD 2,500.00
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 41 USD 3,500.00
Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 94 USD 2,000.00
Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 64 USD 2,000.00

Clients Who Trust Us

麻豆原创 Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At 麻豆原创 we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer鈥檚 needs, be it custom research or syndicated research reports.

Contact Us

麻豆原创 Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected